tradingkey.logo

Daxor Corp

DXR
12.760USD
-0.740-5.48%
Close 11/05, 16:00ETQuotes delayed by 15 min
63.60MMarket Cap
--P/E TTM

Daxor Corp

12.760
-0.740-5.48%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Daxor Corp

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Daxor Corp's Score

Industry at a Glance

Industry Ranking
28 / 30
Overall Ranking
544 / 4682
Industry
Collective Investments

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
23.500
Target Price
+74.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Daxor Corp Highlights

StrengthsRisks
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.22M.
Overvalued
The company’s latest PB is 1.60, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.09K shares, decreasing 11.19% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 28.02K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Collective Investments industry's average is 7.03. Its latest quarterly revenue reached 3.41M, representing a year-over-year decrease of 11.46%, while its net profit experienced a year-over-year decrease of 34.68%.

Score

Industry at a Glance

Previous score
0.00
Change
0

Financials

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

Operational Efficiency

Growth Potential

Shareholder Returns

Daxor Corp's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Collective Investments industry's average is 7.72. Its current P/E ratio is 32.93, which is 297.45% below the recent high of 130.87 and 100.00% above the recent low of 0.00.

Score

Industry at a Glance

Previous score
0.00
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 28/30
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is higher than the Collective Investments industry's average of 6.87. The average price target for Daxor Corp is 23.50, with a high of 25.00 and a low of 22.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts
Buy
Current Rating
23.500
Target Price
+74.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

31
Total
5
Median
4
Average
Company name
Ratings
Analysts
Daxor Corp
DXR
1
Sixth Street Specialty Lending Inc
TSLX
12
FS KKR Capital Corp
FSK
11
SLR Investment Corp
SLRC
9
PennantPark Floating Rate Capital Ltd
PFLT
8
Gladstone Capital Corp
GLAD
8
1
2
3
...
6

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.47, which is lower than the Collective Investments industry's average of 7.94. Sideways: Currently, the stock price is trading between the resistance level at 13.18 and the support level at 10.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.13
Change
-2.66

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(5)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.145
Neutral
RSI(14)
48.388
Neutral
STOCH(KDJ)(9,3,3)
66.357
Neutral
ATR(14)
0.821
High Vlolatility
CCI(14)
-70.988
Neutral
Williams %R
45.006
Neutral
TRIX(12,20)
0.186
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
13.210
Sell
MA10
13.131
Sell
MA20
13.069
Sell
MA50
12.428
Buy
MA100
11.153
Buy
MA200
9.463
Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Collective Investments industry's average of 3.27. The latest institutional shareholding proportion is 2.01%, representing a quarter-over-quarter decrease of 96.59%. The largest institutional shareholder is The Vanguard, holding a total of 49.03K shares, representing 0.98% of shares outstanding, with 0.61% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Joseph Feldschuh UEO
2.55M
--
Feldschuh (Michael Richard)
212.69K
+1.50%
The Vanguard Group, Inc.
Star Investors
49.03K
--
Feldschuh (Jonathan Adam)
35.91K
--
Renaissance Technologies LLC
Star Investors
28.02K
-0.36%
Michel (Robert J)
17.05K
+38.62%
Keyes Stange & Wooten Wealth Management LLC
15.91K
--
Morgan Stanley Smith Barney LLC
3.56K
+3986.21%
Desrosiers (Caleb J.D.)
3.16K
--
SBI Securities Co., Ltd.
3.13K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Collective Investments industry's average is 7.40. The company's beta value is -0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
0.00
Change
0
Beta vs S&P 500 index
-0.00
VaR
+4.91%
240-Day Maximum Drawdown
+100.00%
240-Day Volatility
--

Return

Best Daily Return
60 days
+13.54%
120 days
+13.54%
5 years
+37.55%
Worst Daily Return
60 days
-16.91%
120 days
-16.91%
5 years
-22.30%
Sharpe Ratio
60 days
+1.76
120 days
+2.34
5 years
+0.18

Risk Assessment

Maximum Drawdown
240 days
+100.00%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+0.42
3 years
+0.11
5 years
-0.02
Skewness
240 days
-0.03
3 years
-0.11
5 years
+1.12

Volatility

Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
+4.27%
5 years
+6.78%
Downside Risk-Adjusted Return
120 days
+309.90%
240 days
+309.90%
Maximum Daily Upside Volatility
60 days
+53.12%
Maximum Daily Downside Volatility
60 days
+59.54%

Liquidity

Average Turnover Rate
60 days
+0.59%
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--

Peer Comparison

Collective Investments
Daxor Corp
Daxor Corp
DXR
3.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Fidus Investment Corp
Fidus Investment Corp
FDUS
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Apollo Global Management Inc
Apollo Global Management Inc
APO
7.90 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Crescent Capital BDC Inc
Crescent Capital BDC Inc
CCAP
7.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kayne Anderson BDC Inc
Kayne Anderson BDC Inc
KBDC
7.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Sixth Street Specialty Lending Inc
Sixth Street Specialty Lending Inc
TSLX
7.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI